Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan.
Office of Vaccines and Blood Products, Pharmaceuticals and Medical Devices Agency, Tokyo, 100-0013, Japan.
Ther Innov Regul Sci. 2021 Mar;55(2):304-308. doi: 10.1007/s43441-020-00215-2. Epub 2020 Sep 11.
Japan's rapidly aging population has prompted a change in the country's pharmaceutical care framework from a drug-oriented to a patient-oriented approach. Pharmacies and pharmacists are expected to play central roles in this new patient-oriented approach by reconciling medication and managing polypharmacy, conducting home visits, and providing care to patients in collaboration with local clinics and hospitals. These additional roles are expected to lead to a reduction in the prevalence of adverse effects and improve the quality of life of patients in Japan's aging society. To promote patient-oriented care by pharmacists, these additional roles were legislated in a revision of the Japanese Pharmaceutical and Medical Device Act and other related Act in December 2019. Here, we overview how the revisions affect pharmacies, pharmacists, medical institutions, and outpatients.
日本的人口迅速老龄化促使该国的医药保健框架从以药物为中心转变为以患者为中心。药店和药剂师有望在这个新的以患者为中心的方法中发挥核心作用,通过协调药物和管理多种药物治疗、进行家访,并与当地诊所和医院合作,为患者提供护理。这些额外的角色预计将减少不良反应的发生率,并提高日本老龄化社会中患者的生活质量。为了通过药剂师促进以患者为中心的护理,这些额外的角色在 2019 年 12 月对《日本医药法》和其他相关法案的修订中被立法规定。在这里,我们概述了这些修订如何影响药店、药剂师、医疗机构和门诊病人。